NCT07132528

Comparing the Efficacy and Safety of Chemotherapy Combined With or Without Immunotherapy as an Adjuvant Treatment After Radical Surgery for Patients With Resectable Adenocarcinoma of the Esophagogastric Junction of Gastric Cancer

A Multicenter, Prospective, Real-world Study Comparing the Efficacy and Safety of Chemotherapy Combined With or Without Immunotherapy as an Adjuvant Treatment After Radical Surgery for Patients With Resectable Adenocarcinoma of the Esophagogastric Junction of Gastric Cancer

• Status: Not Yet Recruiting
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 1,000 (estimated)
• Sponsor: Liaoning Cancer Hospital & Institute · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is to evaluate the efficacy and safety of chemotherapy combined with or without Immunotherapy as an Adjuvant Treatment After Radical Surgery for Patients With Resectable Adenocarcinoma of the Esophagogastric Junction of Gastric Cancer

Conditions

• Gastric / Gastroesophageal Junction Adenocarcinoma

Interventions

Type	Name	Description
DRUG	SOX plus PD-1 inhibitor	SOX or XELOX plus PD-1 inhibitor
DRUG	SOX Chemotherapy	SOX or XELOX

Timeline

• Start date: 2025-08-31
• Primary completion: 2028-03-31
• Completion: 2028-09-30
• First posted: 2025-08-20
• Last updated: 2025-08-20